What Early Krystal Biotech Buyers Saw

Krystal Biotech grabbed headlines when its board approved a US$400 million share repurchase program, a rare move for a young genetic medicines specialist that is still investing heavily in trials. For Krystal Biotech shareholders, the return over the past year was 52.0%, including dividends. If you were weighing a buy decision back on 2025-11-06, what exactly did you need to believe about VYJUVEK, the pipeline, and capital allocation for that outcome to feel reasonable?

A Narrative on Simply Wall St is one investor's written case for a company, with its growth, margin and multiple assumptions spelled out. Those assumptions imply an estimated Fair Value.

This theme extends beyond Krystal Biotech. See which of 35 healthcare AI stocks may still merit a closer look.

The Argument Krystal Biotech Investors Were Really Having

The shares cost US$200 at the start of the period, so anyone looking at Krystal Biotech then had to decide which story felt more realistic.

In the bullish May 2025 narrative, the stock looked worth US$252, or 26% above the start price, if VYJUVEK achieved rapid global uptake and revenue grew 51.3% a year with profit margins reaching 66.3%.

The bearish May 2025 view put fair value at US$168, 16% below the start price, and focused on VYJUVEK dependence, pricing and reimbursement pressure, and unpredictable patient treatment pauses as key risks.

What The Results Changed For Krystal Biotech

Krystal Biotech reported VYJUVEK revenue of US$97.8 million in Q3 2025 and US$127.3 million in Q3 2026, which supported the optimistic case on product uptake. Net income moved from US$79.4 million to US$63.1 million and net margin slipped from 81.2% to 49.5%, so the profitability stretch in the bullish story was not yet confirmed. Overall, the evidence cut both ways.

The episode turned on how far high early margins could hold once commercial and R&D spending stepped up. For any biotech with a single lead therapy, track revenue per flagship product against net margin in each quarterly report to see whether early economics are proving durable or being bid down by expansion costs.

What Krystal Biotech’s Price Seems To Be Weighing Now

Krystal Biotech now trades at US$301 after a 52.0% gain over the past year. The selected Narrative’s Fair Value sits above the current price based on its own assumptions rather than any proven outcome.

The Narrative focuses on Vyjuvek cash flow supporting a larger HSV 1 based portfolio. It states that today’s price may not fully reflect late stage pipeline execution across ophthalmology, dermatology and oncology.

"Advancement of Krystal Biotech toward a multiproduct genetic medicines company through late stage programs such as KB803, KB801, KB407, KB111, KB707 and KB408, supported by HSV 1 platform technology designations, could broaden the revenue base beyond Vyjuvek and spread fixed costs across multiple products."

One Narrative disagrees with today's price. → See where this Narrative says Krystal Biotech should trade

Another Way To Play Genetic Bets

Krystal Biotech hinges on a small set of genetic therapies. Your exposure there is tightly bound to a focused pipeline.

Some investors pair that kind of specialist with a broad healthcare platform. The idea is to balance targeted science with a wide mix of medicines and medical technology.

One large group is pushing deeper into oncology, immunology and neuroscience. It is also reshaping its medical device activities and separating slower lines.

R&D spending and early stage deals weigh on near term earnings. They also keep refreshing future drugs and devices that could matter alongside Krystal Biotech’s progress.

That argument has a Narrative and a number behind it. → See the company one Narrative values 16% above its price

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com